Skip to main content

Branded

  • Judge blocks sale of Sanofi’s, Regeneron’s Praluent; companies plan appeal

    WILMINGTON, Del. — U.S. District Court Judge Sue Robinson on Thursday issued an injunction on the sale of Praluent, a PCSK9 inhibitor from Sanofi and Regeneron. Amgen, maker of another PCSK9 inhibitor Repatha, filed the request for the injunction in 2016 after a jury found its patent infringement claims against Sanofi and Regeneron valid. 
     

  • Female Health Company names chief commercial officer

    MIAMI — The Female Health Company/Veru Healthcare on Thursday named Brian Groch the company's chief commercial officer. He will report to Mitchell Steiner, president and CEO of The Female Health Company/Veru Healthcare.

  • Regeneron names new SVP portfolio management

    TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced Wednesday the addition of Dr. Jay Markowitz to its leadership team as its new SVP portfolio management. He joins the pharma company from Capital World Investors, where was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. 
     

  • Sanofi announces U.S. availability of Soliqua 100/33

    PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     

  • Forbes: Pharma innovation getting harder as approvals fall

  • Sanofi sues Novo Nordisk over diabetes drug availability claims

    BRIDGEWATER, N.J. — Sanofi filed a lawsuit against Novo Nordisk for allegedly falsely claiming Sanofi insulin drugs would no longer be available for many U.S. patients, in an effort to promote Novo Nordisk’s competing drug, Reuters reported.

  • FDA approves Biogen’s spinal muscular atrophy drug

    WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Biogen’s Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

  • FDA approves first continuous glucose monitoring system that does not require fingerstick test

    WASHINGTON, D.C. — The U.S. Food and Drug Administration approved its first continuous glucose monitoring system that can be used to make diabetes treatment decisions without confirmation via a traditional fingerstick test. The FDA announced it expanded the approved use of Dexcom’s G5 Mobile Continuous Glucose Monitoring System to allow for replacement of fingerstick blood glucose (sugar) testing for diabetes treatment decisions in people 2 years of age and older with diabetes.

X
This ad will auto-close in 10 seconds